tiprankstipranks
Advertisement
Advertisement

SGIOF Stock Latest News

Shionogi’s Q1 Earnings Surge on Acquisitions, HIV Royalties and Overseas Growth
Company AnnouncementsShionogi’s Q1 Earnings Surge on Acquisitions, HIV Royalties and Overseas Growth
1d ago
Shionogi’s Q1 FY2026 Profit Surges on Strong Revenue Growth, Full-Year Guidance Intact
PremiumCompany Announcements
Shionogi’s Q1 FY2026 Profit Surges on Strong Revenue Growth, Full-Year Guidance Intact
1d ago
SGIOF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
SGIOF Earnings this Week: How Will it Perform?
3d ago
Shionogi’s Redasemtide Stroke Trial Completion: What Investors Should Watch Next
PremiumCompany Announcements
Shionogi’s Redasemtide Stroke Trial Completion: What Investors Should Watch Next
5d ago
SGIOF
Shionogi Targets Pediatric Opioid Side Effects With New Naldemedine Study
PremiumCompany Announcements
Shionogi Targets Pediatric Opioid Side Effects With New Naldemedine Study
7d ago
SGIOF
Shionogi Completes Treasury Share Disposal for Restricted Stock Compensation Plan
PremiumCompany AnnouncementsShionogi Completes Treasury Share Disposal for Restricted Stock Compensation Plan
12d ago
Shionogi to Dispose Treasury Shares for Expanded Restricted Stock Compensation Plan
Premium
Company Announcements
Shionogi to Dispose Treasury Shares for Expanded Restricted Stock Compensation Plan
1M ago
Shionogi Adopts New Policies to Align Management With Capital Costs and Stock Prices
Premium
Company Announcements
Shionogi Adopts New Policies to Align Management With Capital Costs and Stock Prices
1M ago
Shionogi Wins Japan Nod for Pediatric Use of COVID-19 Drug XOCOVA
PremiumCompany Announcements
Shionogi Wins Japan Nod for Pediatric Use of COVID-19 Drug XOCOVA
2M ago
Shionogi and F2G Post Positive Phase 3 Results for Novel Antifungal Olorofim
PremiumCompany Announcements
Shionogi and F2G Post Positive Phase 3 Results for Novel Antifungal Olorofim
2M ago
Ueda Boosts Shionogi to Buy, Raising 12‑Month Target to ¥3,400 on Stronger HIV Franchise and Xocova Upside
PremiumRatings
Ueda Boosts Shionogi to Buy, Raising 12‑Month Target to ¥3,400 on Stronger HIV Franchise and Xocova Upside
2M ago
Shionogi Wins Early FDA Nod for First Oral Post-Exposure COVID-19 Prophylactic
PremiumCompany Announcements
Shionogi Wins Early FDA Nod for First Oral Post-Exposure COVID-19 Prophylactic
2M ago
Shionogi Wins FDA Nod for First Oral COVID-19 Post-Exposure Preventive Drug
PremiumCompany AnnouncementsShionogi Wins FDA Nod for First Oral COVID-19 Post-Exposure Preventive Drug
2M ago
Shionogi Wins China Approval for Naldemedine to Treat Opioid-Induced Constipation
Premium
Company Announcements
Shionogi Wins China Approval for Naldemedine to Treat Opioid-Induced Constipation
2M ago
Shionogi Outlines FY2025 Results, FY2026 Outlook and 2030 Strategy
Premium
Company Announcements
Shionogi Outlines FY2025 Results, FY2026 Outlook and 2030 Strategy
3M ago
Shionogi Lifts FY2025 Earnings and Projects Sharp Revenue Surge for FY2026
PremiumCompany Announcements
Shionogi Lifts FY2025 Earnings and Projects Sharp Revenue Surge for FY2026
3M ago
Shionogi Posts Robust FY2026 Earnings and Projects Strong Growth on Expanded Balance Sheet
PremiumCompany Announcements
Shionogi Posts Robust FY2026 Earnings and Projects Strong Growth on Expanded Balance Sheet
3M ago
Shionogi to Absorb Torii Pharmaceutical in 2027 to Bolster Specialty Drug Business
PremiumCompany Announcements
Shionogi to Absorb Torii Pharmaceutical in 2027 to Bolster Specialty Drug Business
3M ago
Shionogi Lifts Dividend Forecast on Robust HIV and Infectious Disease Growth
PremiumCompany Announcements
Shionogi Lifts Dividend Forecast on Robust HIV and Infectious Disease Growth
3M ago
Shionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise
PremiumCompany AnnouncementsShionogi Seals $2.5 Billion RADICAVA Deal to Build Rare Disease Franchise
4M ago
Shionogi boosts ViiV Healthcare stake as Pfizer exits joint HIV venture
Premium
Company Announcements
Shionogi boosts ViiV Healthcare stake as Pfizer exits joint HIV venture
4M ago
Shionogi Secures ¥300 Billion Bridge Loan for Expanded ViiV Healthcare Stake
Premium
Company Announcements
Shionogi Secures ¥300 Billion Bridge Loan for Expanded ViiV Healthcare Stake
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >